Literature DB >> 24337742

ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.

Laurie Lajoie1, Nicolas Congy-Jolivet, Armelle Bolzec, Valérie Gouilleux-Gruart, Elodie Sicard, Hsueh Cheng Sung, Frank Peiretti, Thierry Moreau, Henri Vié, Béatrice Clémenceau, Gilles Thibault.   

Abstract

FcγRIIIA/CD16A, the low-affinity receptor for the IgG Fc portion expressed on human CD56(dim) NK cells and involved in Ab-dependent cell cytotoxicity, is shed upon NK cell activation. We found that recombinant a disintegrin and metalloprotease (ADAM) 17 cleaved the ectodomain of FcγRIIIA/CD16A and a peptide for which the sequence encompasses aa 191-201 of the FcγRIIIA/CD16A stalk region but not ADAM10. MALDI-TOF analysis revealed that the peptide was cleaved between Ala(195) and Val(196) (i.e., 1 aa upstream of the expected position). This location of the cleavage site was confirmed by the finding that ADAM17 failed to cleave a peptide in which Ala and Val were reversed. ADAM17 was found to be expressed on NK cells, and stimulation with PMA or N-ethyl-maleimide resulted in the shedding of FcγRIIIA/CD16A and CD62L, a specific substrate of ADAM17. Selective inhibition of ADAM17 prevented the shedding of both molecules. Moreover, the shedding of FcγRIIIA/CD16A was strongly correlated with degranulation when a wide range of CD56(dim) NK cell activating receptors were stimulated, whereas both ADAM17-dependent shedding and internalization were involved in FcγRIIIA/CD16A downmodulation when the latter was engaged. Finally, the shedding of FcγRIIIA/CD16A was restricted to activated cells, suggesting that ADAM17 acts mainly, if not exclusively, in cis. Taken together, our results demonstrated for the first time, to our knowledge, at the molecular level that ADAM17 cleaves the stalk region of FcγRIIIA/CD16A and identified its cleavage site. The shedding of FcγRIIIA/CD16A was at least partially ADAM17 dependent, and it may be considered as a marker of FcγRIIIA/CD16A-independent NK cell activation highly correlated with degranulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337742     DOI: 10.4049/jimmunol.1301024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  ADAM17 and CD56low CD16low NK cells.

Authors:  Rizwan Romee; Jeffrey S Miller
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

2.  Response to comment on Multifunctional human CD56low CD16low NK cells are the prominent subset in bone marrow of both pediatric healthy donors and leukemic patients.

Authors:  Helena Stabile; Paolo Nisti; Daria Pagliara; Franco Locatelli; Angela Santoni; Angela Gismondi
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

3.  Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.

Authors:  Kashyap R Patel; Joel D Nott; Adam W Barb
Journal:  Mol Cell Proteomics       Date:  2019-08-29       Impact factor: 5.911

Review 4.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

5.  Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.

Authors:  Hemant K Mishra; Nabendu Pore; Emil F Michelotti; Bruce Walcheck
Journal:  Cancer Immunol Immunother       Date:  2018-07-05       Impact factor: 6.968

Review 6.  Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.

Authors:  Jianming Wu; Hemant K Mishra; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2019-02-20       Impact factor: 4.962

7.  Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.

Authors:  Jacob T Roberts; Kashyap R Patel; Adam W Barb
Journal:  Mol Cell Proteomics       Date:  2019-12-30       Impact factor: 5.911

8.  Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus.

Authors:  Manman Liu; Junli Liu; Xiaoyan Zhang; Yichuan Xiao; Gengru Jiang; Xinfang Huang
Journal:  Clin Rheumatol       Date:  2020-08-14       Impact factor: 2.980

9.  FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis.

Authors:  Jianming Wu; Yunfang Li; Weihua Guan; Kevin Viken; David M Perlman; Maneesh Bhargava
Journal:  Hum Genet       Date:  2016-04-08       Impact factor: 5.881

10.  Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor.

Authors:  Raynier Devillier; Boris Calmels; Sophie Guia; Mohammed Taha; Cyril Fauriat; Bechara Mfarrej; Geoffroy Venton; Eric Vivier; Daniel Olive; Christian Chabannon; Didier Blaise; Sophie Ugolini
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.